Curachem큐라켐
456190 · KONEX · ₩456190 · 큐라켐
- Market cap
- ₩13B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−5.6% from the high
₩6,790Today: ₩7,210 – ₩7,210₩7,640
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M+3.0%
- YTD+0.1%
- 1Y+1.5%
- Volume today
- —
- Traded today
- —
- Listed shares
- 1,834,286
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 46 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Curachem stock overview
Curachem (큐라켐, KRX: 456190) is listed on KONEX, in the Biotech & Pharma sector. The company is a Korean contract research organization (CRO) and contract manufacturing organization (CMO) serving pharmaceutical companies in new drug development. Its shares closed at ₩7,210 on Oct 28, 2026, unchanged on the day, giving it a market value of ₩13B.
Key facts
- Market cap
- ₩13B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 28, 2026
- Main business
- The company is a Korean contract research organization (CRO) and contract manufacturing organization (CMO) serving pharmaceutical companies in new drug development.
Quick answers about Curachem
- What does Curachem do?
- The company is a Korean contract research organization (CRO) and contract manufacturing organization (CMO) serving pharmaceutical companies in new drug development. Its main business is outsourced work for drug developers, including synthesizing radioactive isotopes used in ADME tests on new drug candidates. The business is classified within the pharmaceutical industry, and the filing describes it as a provider of specialized science and technology services.
- What is the market cap of Curachem?
- The market capitalisation of Curachem was ₩13B at the close on Oct 28, 2026.
- Who are the largest shareholders of Curachem?
- According to the latest official filings, the largest reported holders are Mooi Tech (18.08%, as of Jan 10, 2025); DSC Investment (2.74%, as of Mar 24, 2025).
- When is the next earnings report from Curachem?
- Korean companies rarely announce results dates in advance. Based on when Curachem filed the same report in past years, its next annual results is expected between Mar 5, 2027 and Mar 9, 2027.
Company profile
The company is a Korean contract research organization (CRO) and contract manufacturing organization (CMO) serving pharmaceutical companies in new drug development. Its main business is outsourced work for drug developers, including synthesizing radioactive isotopes used in ADME tests on new drug candidates. The business is classified within the pharmaceutical industry, and the filing describes it as a provider of specialized science and technology services.
Written by AI from the company's latest annual report.
- Korean name
- 큐라켐
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 신숙정
- Founded
- Jun 2009
- Listed
- May 2023
- Listed shares
- 1,834,286
- Fiscal year ends
- Month 12
- Website
- www.curachem.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Exercise of Conversion Rights of Convertible SharesJun 22, 2026
- Investor relations (IR) eventMay 21, 2026
- Annual general meeting resultsMar 26, 2026
- Shareholders' meeting calledMar 10, 2026
- Notice of shareholders' meetingMar 10, 2026
Titles in Korean until English translations are added.
Also known as: Curachem / 큐라켐 / 456190 / KRX:456190
Source: KRX statistical information